Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK issues advice on breast implants:

This article was originally published in Clinica

Executive Summary

The UK Department of Health has issued advice on breast implantation detailing: alternative breast reconstruction options; current thinking on the short-term side-effects and long-term potential complications involved in implantation; the issue of pregnancy and breast-feeding; and economic implications. It also provides a checklist of the issues to be considered by prospective patients. The booklet addresses a recommendation from the UK Independent Review Group on silicone gel implants, which in July 1998 called for the provision of free and comprehensive information on breast implantation. Increased concerns over recent years have led to the banning of silicone implants in Canada (since 1992), the US and France. The UK, however, considers that there is insufficient evidence to support a ban.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT074935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel